# FDA Approves Viridian's Lumvoa (veligrotug-vvze) for Thyroid Eye Disease Across Active and Chronic Stages

> fda · REPORTED · 2026-06-26

On June 26, 2026, the FDA approved Lumvoa under Priority Review and Breakthrough Therapy Designation, making it the first thyroid eye disease therapy with labeling covering both active and chronic disease, based on the pivotal THRIVE and THRIVE-2 Phase 3 trials showing rapid proptosis reduction as early as three weeks.

- Company: Viridian Therapeutics
- Sector: therapeutics
- Primary source: https://www.businesswire.com/news/home/20260625016249/en/Viridian-Therapeutics-Announces-U.S.-FDA-Approval-and-Launch-of-Lumvoa-veligrotug-vvze-for-the-Treatment-of-Thyroid-Eye-Disease

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.